

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT
(Under 37 CFR 1.97(b) or 1.97(c))

Docket No.
16833

In Re Application Of: **Anneli Torronen, et al.**

10/6/7 974


Serial No.
Unassigned

Filing Date
July 11, 2003

Examiner
Unassigned

Group Art Unit
Unassigned

Title: **USE OF BETAINE IN FUNCTIONAL PRODUCTS HAVING
BLOOD PRESSURE LOWERING EFFECTS**



Address to:
**Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450**

37 CFR 1.97(b)

1. ☒ The Information Disclosure Statement submitted herewith is being filed within three months of the filing of a national application other than a continued prosecution application under 37 CFR 1.53(d); within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; before the mailing of a first Office Action on the merits, or before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114.

37 CFR 1.97(c)

2. ☐ The Information Disclosure Statement submitted herewith is being filed after the period specified in 37 CFR 1.97(b), provided that the Information Disclosure Statement is filed before the mailing date of a Final Action under 37 CFR 1.113, a Notice of Allowance under 37 CFR 1.311, or an Action that otherwise closes prosecution in the application, and is accompanied by one of:
- ☐ the statement specified in 37 CFR 1.97(e);
- OR**
- ☐ the fee set forth in 37 CFR 1.17(p).

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT
(Under 37 CFR 1.97(b) or 37 CFR 1.97(d))

Docket No.
16833

In Re Application: Anneli Torronen, et al.



Serial No.
Unassigned

Filing Date
July 11, 2003

Examiner
Unassigned

Group Art Unit
Unassigned

**USE OF BETAINE IN FUNCTIONAL PRODUCTS HAVING
BLOOD PRESSURE LOWERING EFFECTS**

Payment of Fee

(Only complete if Applicant elects to pay the fee set forth in 37 CFR 1.17(p))

- ☐ A check in the amount of _____ is attached.
- ☒ The Director is hereby authorized to charge and credit Deposit Account No. **19-1013/SSMP** as described below.
- ☐ Charge the amount of _____
- ☒ Credit any overpayment.
- ☒ Charge any additional fee required.

Certificate of Transmission by Facsimile*

I certify that this document and authorization to charge deposit account is being facsimile transmitted to the United States Patent and Trademark Office (F:

(Date)

Signature

Typed or Printed Name of Person Signing Certificate

Certificate of Mailing by First Class Mail

I certify that this document and fee is being deposited on **September 3, 2003** with the U.S. Postal Service as first class mail under 37 C.F.R. 1.8 and is addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Signature

Frank S. DiGiglio

Typed or Printed Name

*This certificate may only be used if paying by deposit account.

Signature

Dated: September 3, 2003

Frank S. DiGiglio
Registration No. 31,346
SCULLY, SCOTT, MURPHY & PRESSER
400 Garden City Plaza
Garden City, NY 11530
(516)742-4343
FSD:SRV/nis

CC:

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT**(Under 37 CFR 1.97(b) or 1.97(c))**Docket No.
16833

In Re Application Of: Anneli Torronen, et al.

Serial No.
UnassignedFiling Date
July 11, 2003Examiner
UnassignedGroup Art Unit
UnassignedTitle: **USE OF BETAINES IN FUNCTIONAL PRODUCTS HAVING
BLOOD PRESSURE LOWERING EFFECTS**Address to:
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450**37 CFR 1.97(b)**

1. ☒ The Information Disclosure Statement submitted herewith is being filed within three months of the filing of a national application other than a continued prosecution application under 37 CFR 1.53(d); within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; before the mailing of a first Office Action on the merits, or before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114.

37 CFR 1.97(c)

2. ☐ The Information Disclosure Statement submitted herewith is being filed after the period specified in 37 CFR 1.97(b), provided that the Information Disclosure Statement is filed before the mailing date of a Final Action under 37 CFR 1.113, a Notice of Allowance under 37 CFR 1.311, or an Action that otherwise closes prosecution in the application, and is accompanied by one of:
- ☐ the statement specified in 37 CFR 1.97(e);
- OR**
- ☐ the fee set forth in 37 CFR 1.17(p).

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT
(Under 37 CFR 1.97(b) or 1.97(c))

Docket No.
16833

In Re Application: Anneli Torronen, et al. SEP 05 2003

Serial No.
Unassigned

Filing Date
July 11, 2003

Examiner
Unassigned

Group Art Unit
Unassigned

**USE OF BETAINE IN FUNCTIONAL PRODUCTS HAVING
BLOOD PRESSURE LOWERING EFFECTS**

Payment of Fee

(Only complete if Applicant elects to pay the fee set forth in 37 CFR 1.17(p))

- ☐ A check in the amount of _____ is attached.
- ☒ The Director is hereby authorized to charge and credit Deposit Account No. **19-1013/SSMP** as described below.
- ☐ Charge the amount of _____
- ☒ Credit any overpayment.
- ☒ Charge any additional fee required.

Certificate of Transmission by Facsimile*

I certify that this document and authorization to charge deposit account is being facsimile transmitted to the United States Patent and Trademark Office (F:

(Date)

Signature

Typed or Printed Name of Person Signing Certificate

Certificate of Mailing by First Class Mail

I certify that this document and fee is being deposited on **September 3, 2003** with the U.S. Postal Service as first class mail under 37 C.F.R. 1.8 and is addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Signature

Frank S. DiGiglio

Typed or Printed Name

*This certificate may only be used if paying by deposit account.

Signature

Dated: September 3, 2003

Frank S. DiGiglio
Registration No. 31,346
SCULLY, SCOTT, MURPHY & PRESSER
400 Garden City Plaza
Garden City, NY 11530
(516)742-4343
FSD:SRV/nis

CC:



PATENTS

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants:	Anneli Torronen, et al.	Examiner:	Not assigned
Serial No:	Unassigned	Art Unit:	Unassigned
Filed:	July 11, 2003	Docket:	16833
For:	USE OF BETAINE IN FUNCTIONAL PRODUCTS HAVING BLOOD PRESSURE LOWERING EFFECTS		Dated: September 3, 2003

Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:


In accordance with 37 C.F.R. §§ 1.97 and 1.98, it is requested that the following references, which are also listed on the attached Form PTO-1449, be made of record in the above-identified case.


1. U.S. Patent No. 4,563,467, dated January 7, 1986, issued to Soler;
2. U.S. Patent No. 4,902,718, dated February 20, 1990, issued to Bayless et al.;
3. U.S. Patent No. 589,056, dated January 12, 1999, issued to Kalvinsh et al.;

CERTIFICATE OF MAILING UNDER 37 C.F.R. §1.8(a)

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner of Patents, P. O. Box 1450, Alexandria, VA 22313-1450 on September 3, 2003.

Dated: September 3, 2003


Frank S. DiGiglio



INFORMATION DISCLOSURE CITATION

Use several sheets if necessary)

Docket Number (Optional)
16833Application Number
Unassigned

Applicant(s)

Anneli Törrönen, et al.

Filing Date

August 22, 2003

Group Art Unit

Unassigned

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	REF	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
		4,563,467	01/07/86	Jose E. Soler			
		4,902,718	02/20/90	Robert K. Bayless, et al.			
		5,859,056	01/12/99	Ivars Kalvinsh, et al.			
		4,663,348	05/05/87	Lester Chafetz, et al.			
		3,090,725	05/21/63	Frederick C. Copp, et al.			
		5,126,291	06/30/92	Allan Wissner			

FOREIGN PATENT DOCUMENTS

	REF	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
		02/055069 A1	07/18/02	PCT				
		00/27386	05/18/00	PCT				
		97/06794	02/27/97	PCT				
		94/0957	02/11/94	So. Africa				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

		Mitsuru Tamada, et al., "Maokonine, Hypertensive Principle of Ephedra Roots", <u>Journal of Medicinal Plant Research</u> , vol. 34, pp. 290-293, (1978)
		Hana Rauchova, et al., "The effect of chronic L-carnitine treatment on blood pressure and plasma lipids in spontaneously hypertensive rats", <u>European Journal of Pharmacology</u> , 342, pp. 235-39, (1998)


EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Docket Number (Optional)
16833Application Number
Unassigned

INFORMATION DISCLOSURE CITATION
(Use several sheets if necessary)



Applicant(s)

Anneli Törrönen, et al.

Filing Date

January 12, 2001

Group Art Unit

Unassigned

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	REF	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

	REF	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
		1012546 A6	12/05/00	Belgium			X	
		01/00047 A1	01/04/01	PCT				
		00/25764	05/11/00	PCT				
		0781554 A1	7/2/97	EPA				
		840081-5	12/5/88	Sweden			Eng. Abstract	

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.